Socio-economic inequalities in the use of drugs for the treatment of chronic diseases in Italy

A. Di Filippo†, S. Perna†, A. Pierantozzi, F. Milozzi, F. Fortinguerra, N. Caranci, L. Moro, N. Agabiti, V. Belleudi, G. Cesaroni, A. Nardi, T. Spadea, R. Gnavi and F. Trotta

Abstract

Background: Since the use of medicines is strongly correlated to population health needs, higher drug consumption is expected in socio-economical deprived areas. However, no systematic study investigated the relationship between medications use in the treatment of chronic diseases and the socioeconomic position of patients. The purpose of the study is to provide a description, both at national level and with geographical detail, of the use of medicines, in terms of consumption, adherence and persistence, for the treatment of major chronic diseases in groups of population with different level of socioeconomic position.

Methods: A cross-sectional study design was used to define the “prevalent” users during 2018. A longitudinal cohort study design was performed for each chronic disease in new drug users, in 2018 and the following year. A retrospective population-based study, considering all adult Italian residents (i.e. around 50.7 million people aged ≥ 18 years).

Different medications were used as a proxy for underlying chronic diseases: hypertension, dyslipidemia, osteoporosis, diabetes and chronic obstructive pulmonary disease. Only “chronic” patients who had at least 2 prescriptions within the same subgroup of drugs or specific medications during the year were selected for the analysis. A multidimensional measures of socio-economic position, declined in a national deprivation index at the municipality level, was used to identify and estimate the relationship with drug use indicators. The medicine consumption rate for each pharmacological category was estimated for prevalent users while adherence and persistence to pharmacologic therapy at 12 months were evaluated for new users.

Results: The results highlighted how the socioeconomic deprivation is strongly correlated with the use of medicines: after adjustment by deprivation index, the drug consumption rates decreased, mainly in the most disadvantaged areas, where consumption levels are on average higher than in other areas. On the other hand, the adherence and persistence indicators did not show the same trend.

Conclusions: This study showed that drug consumption is influenced by the level of deprivation consistently with the distribution of diseases. For this reason, the main levers on which it is necessary to act to reduce disparities in health status are mainly related to prevention. Moreover, it is worth pointing out that the use of a municipal deprivation indicator necessarily generates an ecological bias, however, the experience of the present study, which for the

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Key points
• Question: Is there a relationship (in terms of consumption, adherence and persistence) between socioeconomic position of people with chronic disease and chronic medications use?
  • Findings: Socioeconomic position was strongly correlated with the use of medications, coherently with the social gradients in the occurrence of most diseases; the analysis of adherence and persistence among groups of population with different socioeconomic deprivation showed a lack of a univocal gradient among the Italian regions.
  • Meaning: It is necessary to improve prevention of chronic diseases to reduce disparities in health status.

Introduction
Health inequalities associated with socio-economic position (SEP) have been observed in all European countries [1]. Several studies published over the last 20 years showed that people with a higher social and economic position have better health status. Since available evidence showed that health disparities can be reduced by improving the socio-economic position, this issue is among the main priorities in public health policies [1–3].

In Italy, equity in access to healthcare services, including medicines, is one of the main objectives of the National Health Service (NHS) [4]. In this context, the “Essential Levels of Assistance” (LEA) delineate all the healthcare services that the NHS is required to provide to all Italian citizens (free of charge or upon a co-payment), regardless the individual ability to pay, income or region of residence, with the aim to ensure uniformity in healthcare assistance throughout the national territory [5]. In particular, LEAs also measure the appropriateness and the universality of territorial pharmaceutical care for people with chronic diseases [6].

However, despite the growing improvement in health conditions observed in recent years, there is still some evidence that the SEP is affecting the health status in Italy.

Moreover, wide differences persist also at geographical level: Southern Italy has more critical health indicators than other Italian areas. Such geographical variability depends on multiple factors; first of all the different organization of Regional Health Services (RHS), which could determine disparities in healthcare services and opportunities leading to an exacerbation of individual disadvantage of the lowest socioeconomic groups [7–13]. It’s known that drug use can be considered as a proxy indicator of chronic diseases and consequently of health status [14].

With regard to the Italian pharmaceutical assistance, few studies examined the role of socioeconomic factors in both access and optimal assumption of medicines; they were limited to single therapeutic categories or specific geographical areas and led to inconsistent results.

For example, a cohort study of about 70 thousand patients living in the city of Milan shows that, compared with people with the highest income, those with the lowest income were more likely to start antihypertensive and antidiabetic drug therapy; another study involving a total of 175 Italian health districts (3.3 million children/adolescents) found that lower income at the district level correlated with higher rates of antibiotic and anti-asthmatic drug prescriptions; similar results on antibiotic consumption are reported in a study of municipalities in a southern Italian region [15–18].

To date, no nationwide study, covering the majority of chronic diseases, has been performed to explore the correlation of medications use with the socioeconomic position of patients. The access to highest-quality medications for the management of both acute and chronic diseases, regardless of race and ethnicity, socio-economic position, or availability of resources, plays a decisive role for the quality of life. This goal could be referred as pharmacoequity [19].

The present study aims to compare the use of medicines – measured through consumption rate, adherence and persistence to drug therapy—prescribed for the major chronic diseases in Italy among groups of population characterized by a different level of SEP, measured through a deprivation index (DI). Such description of the phenomenon can be useful for national and regional interventions to be implemented in the country.

Methods
Data sources
A retrospective population-based study, considering all adult Italian residents (i.e. around 50.7 million people), was performed in order to compare the use of medicines prescribed for major chronic diseases in Italy among groups of population with different SEP. Data sources used to identify the study population were: the Italian pharmaceutical prescriptions database and the...
official registry of Italian resident population stratified by sex, age and municipality of residence for the year 2018 [20]. The pharmaceutical prescriptions database includes all individual records for each drug prescription dispensed by community pharmacies and reimbursed by the Italian NHS.

**Explanatory socio-economic variable**
Considering the absence of socio-economic variables at individual level in pharmaceutical prescriptions database, a multidimensional measures of SEP defined as a national deprivation index (DI) was used to estimate the association with drugs use indicators. The DI used in this analysis is a composite measure, developed in 2010 [21] and further updated using data from 2011 census [22]; it takes into account five indicators representing material and social disadvantages: i) percentage of subjects with primary school education level or below, ii) percentage of the economically active subjects that is either unemployed or looking for a first job, iii) percentage of rented dwellings, iv) percentage of one parent families, and v) overcrowding (inhabitants per 100 m² of living area). In order to study the relationship between SEP and drugs use, the Italian municipalities population were categorized by three tertiles of deprivation; the first tertile represented the least deprived group of population while the third tertile included the most deprived cases. Then, patients were assigned to each tertile on the basis of the DI referred to his municipality of residence. Given the high heterogeneity of distributions at the municipal level, to improve the readability of the results, the maps were represented by province, where each province was obtained from the weighted average of its constituent municipalities. Consistently, therefore, the DI map was also represented at the provincial level and divided into tertiles of deprivation. As shown from the progressive shade of colors, from lighter blue for provinces less deprived to dark blue for provinces more deprived, it can be observed how the DI is distributed differently along the Italian peninsula (eFigure 1).

**Chronic diseases and medications considered**
Different medications were used as a proxy of underlying chronic diseases for all subjects aged ≥ 18 years: hypertension, dyslipidemia, osteoporosis, diabetes and chronic obstructive pulmonary disease (COPD). The medicines were classified according to the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC coding) classification system (see supporting information of table eTable 1 for further details on pharmacotherapy categories selected for the analysis) [23].

**Study designs and outcome indicators**
Two observational study designs were considered to analyse the following three indicators on drugs use, medicine consumption rate, adherence and persistence to a pharmacological treatment:

- a cross-sectional design for the evaluation of consumption rate, which was used to define the prevalent users, i.e. all “chronic” patients who had a prescription for the selected pharmacological categories in the period from 1st January 2018 to 31st December 2018 (eTable 1);
- a longitudinal cohort design, to estimate one-year adherence and persistence among new drug users. To this aim, we considered as incident users all people who received at least one prescription in the period between 1st January 2018 and 31st December 2018 (index period) and who did not receive prescriptions for drugs belonging to the same therapeutical category in the previous 12 months (wash-out period). Subsequently, only incident users were followed for 365 days from the date of enrollment (index date) (see eTable 1).

The medicine consumption rate for each pharmacological category was defined as ratio between the total number of days of therapy (DOT) prescribed to patients and the residing population. DOT were calculated considering the Daily Defined Dose (DDD) associated to each prescribed medication.

The adherence to pharmacologic therapy was evaluated through the Medication Possession Ratio (MPR), calculated as the ratio of the amount of days a patient had his/her medicine on the time interval between first and last prescriptions. High-adherent patients were those with a number of days covered by pharmacologic therapy greater than 75% of the observed time period (i.e. MPR ≥ 75%) [24].

The persistence to pharmacologic therapy was defined as the time period between the initiation and the interruption of a prescribed drug treatment, considering as “permissible gap” an interruption of drug therapy shorter than 60 days [25].

**Statistical analysis**
The medicine consumption rate was adjusted through a direct standardization, considering as standard population the official registry on Italian resident population for the year 2018 [20]. The adult population was stratified into 7 age groups (18–34 years; 35–44 years; 45–54 years; 55–64 years; 65–74 years; 75–84 years; ≥ 85 years).
The proportion of high adherent patients, adjusted for age and DI, was estimated through Poisson regression models. Persistence was estimated as the probability of therapeutic maintenance (“survival to the event”) after a fixed number of days from the beginning of therapeutic treatment [26]. In particular, the probability to be persistent after 12 months of treatment, adjusting for age and DI, was evaluated through the semi-parametric Cox regression model for survival analysis. The related 95% confidence intervals (CI) were calculated for each indicator.

Drug utilization analyses were stratified by tertile of deprivation. In a geographical analysis, the drug utilization indicators were represented on maps at provincial level and the DI was considered as a potential confounding variable of context and thus considered to adjust the outcomes indicators. In the graphical representation of each indicator the interquartile range (IQR) was reported. All results, adjusted for age, were calculated for both women and men.

For the graphical representation of the indicators at the provincial level, the existence of a spatial dependence among contiguous territorial areas was taken into account [27]. In fact, a Kernel estimator was used in order to obtain more reliable estimates in the proximity of the provincial boundaries to mitigate the variability related to this structural component of the phenomenon under consideration.

The statistical analyses were performed using SAS software, version 9.4 (SAS Institute, North Carolina, US).

### Results

Overall, higher levels of medication consumption rate were observed in men in comparison to women for all the selected therapeutic categories (170.8 DDD vs 141.8 DDD per capita for hypertension; 21.8 DDD vs 15.1 DDD per capita for diabetes; 44.3 DDD vs 30.0 DDD per capita for dyslipidemias; 9.9 DDD vs 6.5 DDD per capita for COPD) except for osteoporosis (0.6 DDD vs 6.6 DDD per capita). At the geographical level higher levels of consumption emerged in Southern Italy. The SEP was strongly correlated with medicine consumption rates, which were higher among subjects living in the most disadvantaged areas. This phenomenon was evident for almost all the chronic conditions analyzed, particularly for antihypertensive, hypolipidemic and antidiabetic medications as well as for COPD therapy, regardless of patient’s gender; similar results were observed for anti-osteoporotic medications in women. Removing the effect of deprivation, the medicines consumption decreased in the most deprived areas, mainly in Southern Italy (Table 1, Figs. 1 and 2, eFigures 2, 3 and 4).

Adherence and persistence to the considered pharmacological treatments were found to be suboptimal at national level; moreover, a decreasing geographical North–South gradient was observed for both indicators. Women were less adherent to treatments than men (57.8% vs 48.5% for hypertension; 37.6% vs 31.6% for diabetes; 51.9% vs 40.5% for dyslipidemias; 36.1% vs 30.5% for COPD). The only exception was observed for anti-osteoporotic medications (close to 70% for both

### Table 1 Medicine consumption rate in “prevalent” subjects treated for chronic diseases, standardized by age and stratified by gender and tertile of deprivation

| Tertiles of deprivation | Men (≥ 18 year) | Women (≥ 18 year) |
|-------------------------|----------------|------------------|
|                         | Standardized consumption rate (95% CI) | Age-standardized consumption rate | Standardized consumption rate (95% CI) | Age-standardized consumption rate |
| **Hypertension**        |                |                  |                |                  |
| 1                       | 165.30 (165.29–165.31) | 170.85 | 128.10 (128.10–128.11) | 141.78 |
| 2                       | 169.08 (169.07–169.09) | 138.22 | 159.92 (159.91–159.93) |                  |
| 3                       | 178.20 (178.19–178.21) |                  |                  |                  |
| **Dyslipidemia**        |                | 44.35            | 26.26 (26.26–26.26) | 30.03 |
| 1                       | 42.30 (42.30–42.31) |                  |                  |                  |
| 2                       | 43.14 (43.13–43.14) |                  |                  |                  |
| 3                       | 47.68 (47.68–47.69) |                  |                  |                  |
| **Osteoporosis**        |                | 0.56             | 5.52 (5.52–5.53) | 6.57 |
| 1                       | 0.59 (0.59–0.59) |                  |                  |                  |
| 2                       | 0.56 (0.56–0.56) |                  |                  |                  |
| 3                       | 0.51 (0.51–0.51) |                  |                  |                  |
| **Diabetes**            |                | 21.80            | 11.92 (11.92–11.93) | 15.09 |
| 1                       | 19.57 (19.57–19.58) |                  |                  |                  |
| 2                       | 20.52 (20.52–20.52) |                  |                  |                  |
| 3                       | 25.00 (24.99–25.00) |                  |                  |                  |
| **COPD**                |                | 9.87             | 6.12 (6.12–6.12) | 6.50 |
| 1                       | 8.63 (8.63–8.63) |                  |                  |                  |
| 2                       | 9.50 (9.50–9.50) |                  |                  |                  |
| 3                       | 11.42 (11.41–11.42) |                  |                  |                  |
women and men). Levels of persistence to treatments observed for women were lower than men (54.2% in men and 45.0% for hypertension; 43.2% vs 36.8% for diabetes; 51.8% vs 43.4% for dyslipidemias; 51.8% vs 43.4% for COPD). By contrast, persistence at 12 months for anti-osteoporotic medications was 51.8% in women and 43.4% in men. With regard to the relationship with SEP at national level, both adherence and persistence were generally higher among people living in more deprived areas, however, a wide variability was observed within the different regions: a clear trend among different tertiles of deprivation was not observed in none of the Italian Regions. Removing the effect of deprivation, adherence and persistence levels remained constant, suggesting that
the effect of deprivation is not appreciable in this context (Table 2, Fig. 3, eFigure 5).

A summary of the main evidence for each considered chronic disease is reported below. Tables 1 and 2 show the results for the five diseases, whereas the maps refer to the only two diseases with the highest prevalence rates (hypertension and diabetes).

**Discussion**

This is the first study evaluating the relationship between SEP and several drug utilization indicators carried out in Italy at national level and covering the majority of chronic conditions. To our knowledge, previous studies were limited to single Italian regions or smaller samples [15–18].
Table 2 Adherence and persistence at 12 months (%) in “incident” subjects following a pharmacological treatment for chronic diseases, adjusted by age and stratified by gender and tertile of deprivation

| Tertiles of deprivation | Incidents (n) | Adherence (%)<sup>a</sup> | Adherence adjusted for age % | Adherence adjusted for age and DI % | Relative difference between Adherence adjusted for age and adjusted for age and DI | Persistence (%)<sup>b</sup> | Persistence adjusted for age % | Persistence adjusted for age and DI % | Relative difference between Persistence adjusted for age and adjusted for age and DI |
|-------------------------|----------------|-----------------------------|-------------------------------|-----------------------------------|--------------------------------------------------------------------------------|-----------------------------|-----------------------------|----------------------------------|--------------------------------------------------------------------------------|
| Hypertension Men (≥ 18 year) | 1 | 152,364 | 58.7 (56.9–60.6) | 57.8 | 57.9 | 0.1% | 53.4 (53.1–53.6) | 54.2 | 54.2 | 0.0% |
| | 2 | 160,629 | 58.4 (56.6–60.2) | 57.1 | 57.5 | 0.4% | 54.6 (54.4–54.8) | 54.6 | 54.6 | 0.0% |
| | 3 | 177,145 | 56.5 (54.9–58.3) | 56.3 | 56.3 | 0.0% | 54.3 (54.2–54.7) | 54.3 | 54.3 | 0.0% |
| Women (≥ 18 year) | 1 | 159,560 | 49.5 (47.9–51.1) | 48.5 | 48.5 | 0.1% | 44.1 (43.9–44.4) | 45.0 | 45.0 | 0.0% |
| | 2 | 167,975 | 49.2 (47.7–50.8) | 48.1 | 48.1 | 0.0% | 45.5 (45.3–45.7) | 45.5 | 45.5 | 0.0% |
| | 3 | 176,908 | 47.6 (45.3–48.5) | 47.4 | 47.4 | 0.0% | 45.8 (45.2–45.6) | 45.8 | 45.8 | 0.0% |
| Dyslipidemia Men (≥ 18 year) | 1 | 103,990 | 53.8 (52.8–54.8) | 51.9 | 52.1 | 0.4% | 53.8 (53.5–54.1) | 51.8 | 51.7 | 0.1% |
| | 2 | 112,564 | 52.7 (51.7–53.6) | 50.2 | 50.2 | 0.0% | 52.8 (52.5–53.1) | 52.8 | 52.8 | 0.0% |
| | 3 | 137,595 | 50.0 (49.1–50.8) | 48.4 | 48.4 | 0.0% | 50.2 (49.3–50.6) | 50.2 | 50.2 | 0.0% |
| Women (≥ 18 year) | 1 | 103,113 | 42.3 (41.4–43.2) | 40.5 | 40.5 | 0.0% | 44.2 (43.9–44.5) | 43.4 | 43.4 | 0.1% |
| | 2 | 114,359 | 41.0 (40.1–42.1) | 39.5 | 39.5 | 0.0% | 42.4 (42.1–42.5) | 41.6 | 41.6 | 0.0% |
| | 3 | 146,235 | 38.8 (38.1–39.5) | 37.3 | 37.3 | 0.0% | 42.1 (41.9–42.4) | 42.1 | 42.1 | 0.0% |
| Osteoporosis Men (≥ 18 year) | 1 | 5,056 | 72.0 (69.6–74.4) | 67.8 | 67.8 | 0.1% | 49.5 (48.1–50.9) | 43.4 | 43.0 | 0.0% |
| | 2 | 5,121 | 68.2 (65.9–70.5) | 63.5 | 63.5 | 0.0% | 44.5 (43.4–45.6) | 36.1 | 35.3 | 0.0% |
| | 3 | 5,121 | 63.6 (61.5–65.8) | 58.9 | 58.9 | 0.0% | 43.5 (42.7–44.3) | 36.1 | 35.3 | 0.0% |
| Women (≥ 18 year) | 1 | 39,514 | 71.4 (70.0–73.0) | 69.0 | 69.0 | 0.4% | 55.4 (54.9–55.9) | 51.8 | 51.9 | 0.2% |
| | 2 | 44,308 | 70.7 (69.2–72.1) | 68.3 | 68.3 | 0.4% | 53.0 (52.6–53.5) | 49.4 | 49.4 | 0.0% |
| | 3 | 54,808 | 68.2 (66.9–69.7) | 66.6 | 66.6 | 0.0% | 48.3 (47.9–48.7) | 48.3 | 48.3 | 0.0% |
| Diabetes Men (≥ 18 year) | 1 | 36,431 | 41.9 (39.9–43.9) | 37.6 | 37.6 | 1.2% | 44.0 (43.4–44.5) | 43.2 | 43.2 | 0.0% |
| | 2 | 43,054 | 37.4 (35.6–39.1) | 33.8 | 33.8 | 1.2% | 42.7 (42.3–43.2) | 42.7 | 42.7 | 0.0% |
| | 3 | 54,985 | 35.0 (33.5–36.5) | 31.5 | 31.5 | 1.2% | 43.1 (42.7–43.5) | 43.1 | 43.1 | 0.0% |
| Women (≥ 18 year) | 1 | 29,196 | 37.1 (35.2–39.2) | 31.6 | 31.6 | 1.8% | 38.3 (37.8–38.9) | 36.8 | 36.8 | 0.0% |
| | 2 | 39,511 | 31.9 (30.4–33.6) | 28.5 | 28.5 | 1.8% | 36.0 (35.5–36.4) | 36.0 | 36.0 | 0.0% |
| | 3 | 50,436 | 28.3 (27.0–29.7) | 25.0 | 25.0 | 1.2% | 36.5 (35.6–37.0) | 36.5 | 36.5 | 0.0% |
| COPD Men (≥ 18 year) | 1 | 40,013 | 37.1 (35.8–38.5) | 36.1 | 36.1 | 0.8% | 24.8 (24.4–25.3) | 23.7 | 23.7 | 0.0% |
| | 2 | 46,773 | 37.2 (36.0–38.5) | 36.2 | 36.2 | 0.8% | 25.0 (24.6–25.4) | 23.7 | 23.7 | 0.0% |
| | 3 | 67,152 | 34.8 (33.8–35.8) | 33.4 | 33.4 | 0.8% | 22.2 (21.9–22.5) | 21.9 | 21.9 | 0.0% |
| Women (≥ 18 year) | 1 | 42,549 | 32.1 (30.9–33.3) | 30.5 | 30.5 | 0.7% | 19.9 (19.5–20.3) | 18.0 | 18.0 | 0.0% |
| | 2 | 52,046 | 31.2 (30.2–32.3) | 30.0 | 30.0 | 0.7% | 18.9 (18.6–19.3) | 17.8 | 17.8 | 0.0% |
| | 3 | 70,427 | 29.0 (28.2–29.9) | 28.0 | 28.0 | 0.7% | 16.2 (15.9–16.5) | 15.9 | 15.9 | 0.0% |

<sup>a</sup> High adherence, calculated by MPR, was defined as therapeutic coverage ≥ 75% of the observation period (median (IQR): 284 (139–337)). The percentages were adjusted by age (see statistical methods for further details)

<sup>b</sup> Persistence to treatment was assessed in the 365 days following the first prescription (data index). An interruption to treatment occurs if the subject does not have a prescription delivered within 60 days (assessed on the basis of DDD). The percentages were adjusted by age (see statistical methods for more details)
Overall, the medicine consumption rates seem to be consistent with what is known on the epidemiology of chronic diseases in Italy and with the effects of deprivation on them. For example, the consumption rates of antihypertensive drugs are coherent with the results of several surveys conducted by Health Search, the research institute of the Italian Society of General Practitioners, which showed a higher prevalence of hypertension in the South of Italy than the Center and North and in poor subjects, compared to highly educated ones [28, 29]. A similar trend was also observed for the antidiabetic drugs [30, 31]. This aspect is more evident for antiosteoporotic drugs: since osteoporosis is a disease mainly affecting women, the consumption rate of these medications was 10 times higher in female than in male population [32]; only for dyslipidemias the medication consumption rates were lower in women than in men, despite the high prevalence of these disorders in both sex [29].

The results showed that SEP was strongly correlated with the use of medications, coherently with the social gradients in the occurrence of most diseases, suggesting that drugs are prescribed consistently with the health needs of the population. Therefore, they are in line with the “pharmacoequity” target expressed by the universality principle of the Italian NHS [19]. In Italy, in fact, the universal health system guarantees all people with free access to treatment, both in terms of drug consumption and access to the general practitioner.

High rates of consumption per capita were registered in areas characterized by high level of deprivation, in particular for therapeutic categories used to treat diabetes, hypertension, dyslipidemia, and, in women, for osteoporosis. An increasing trend of medicine consumption rates, from less to more deprived municipalities, was evident in almost all Italian regions. The adjustment by deprivation tertile sharply modified this trend causing a significantly reduction of consumption levels, especially in the most deprived provinces of Southern Italy thus reducing the difference between North and South.

This phenomenon could be probably explained by the worst health status of the subjects living in the poor areas, which could be associated with an unhealthy lifestyle. In fact, it is known that the medicine consumption rate is correlated with several factors, some are strictly related to the individual, such as the severity of the disease, awareness of health condition or compliance to therapy, and they may also be related to the socioeconomic level of individuals [8, 29]. Moreover, other factors associated with drug consumption are related to specific health care service characteristics, such as the different prescriptive behavior of medical doctors, and the different organization of local health services, including the access to general practitioners as well as the distribution of community pharmacies on the territories, which could explain part of consumption variability across geographical areas and among different Italian regions.

The average levels of adherence and persistence to pharmacological treatments were generally suboptimal; for both indicators a decreasing geographical North–South gradient was observed. However, the interpretation of the association with SEP was difficult because of the wide heterogeneity within the Italian regions and the lack of a univocal gradient: the national trend of deprivation tertiles, in fact, was not always coherent with the trend of intra-regional tertiles. On the contrary to what was observed in medicine consumption rates, where most of the variability disappeared after adjusting for deprivation, the levels of adherence and persistence did not change after removing the effect of deprivation, confirming the invariance of the two indicators with SEP. This result seems in contrast with a recent review that shows a positive impact of higher socioeconomic position on adherence for several chronic diseases, in particular for cardiovascular conditions [33]. However, other studies reported conflicting results and the evidence is not often conclusive [15, 34–43].

Adherence is a multifactorial phenomenon that can be affected by various factors both at individual and context level. Adherence to treatment for chronic diseases can be influenced by the territorial health care organization: for example, for diabetes, diagnostic-therapeutic care assistance is guaranteed by the presence of diabetes centres throughout the national territory. This organization, by increasing patient care, indirectly improves equity in access to pharmacological treatments [39, 40]. On the other hand, where therapeutic care is entrusted only to the general practitioner, individual characteristics and behaviours may play a key role on treatment compliance and the SEP indicator based on municipal area may not be suitable, suggesting the need to perform further studies using an individual SEP indicator.

So, as we reported above, the main healthcare challenge in Italy is to work hard on lifestyle and prevention starting from the most disadvantaged contexts in order to reduce inequities, rather than acting on access to therapies and treatments for chronicity.

The main limitation of the study is the lack of socio-economic indicators at individual level. The use of a municipal deprivation indicator necessarily generates an ecological bias, whose entity is difficult to quantify. This bias, moreover, may have a greater impact on adherence and persistence, not allowing to detect the potential impact of socio-economic determinants, which in these cases presumably act on an individual level (unlike what is observed for consumption rates, where contextual socio-economic factors captured by the aggregate index highlighted an
Fig. 3  Adherence and persistence to treatment at 12 months (%) in adults (≥ 18 years) by province† adjusted by age
impact. In order to evaluate the inclusion of wide geographical aggregated in the analysis, sensitivity analyses were conducted for all indicators, restricting the analysis to municipalities with less than 30,000 inhabitants, that is the threshold indicated for the validity of the use of the deprivation index [44]; the results showed no significant differences compared to the main analysis (results not shown).

A further limitation was the inability to trace medicines purchased privately by Italian citizens, which are not recorded by the pharmaceutical information system. Since the private purchase of drugs is higher for the wealthier subjects than for those more disadvantaged, it could lead to an overestimation of the large variability in the consumption rate observed for some therapeutic category.

Nevertheless, the study confirmed the analytical potential of pharmaceutical prescriptions databases: the population taken into analysis is in fact the whole adult Italian population (about 50.7 million people) for which the entire prescribing history was available along with socio-economic information at the municipality level.

Conclusion
Drug consumption is influenced by the level of deprivation consistently with the distribution of diseases. This phenomenon could be probably explained by the worst health status of the subjects living in the poor areas, which could be associated with an unhealthy lifestyle, so the main levers on which it is necessary to act to reduce disparities in health status are mainly related to prevention.

The nationwide comparative approach of health care-related phenomena is a fundamental stimulus to improve health assistance, from the central to the local level of government. The experience of the present study, which for the first-time deals with the complex and delicate issue of equity in pharmaceutical assistance, lays the groundwork for new insights that could overcome the limitations of the methodology used here and make a further contribution to the understanding of this phenomenon.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12939-022-01772-8.

Acknowledgements
Drug Inequalities study group: Silvia Minim Cammarata, Aurora Di Filippo, Filomena Fortinguerra, Federica Milozzo, Serena Perna, Andrea Pierantozzi, Giuseppe Traversa, Francesco Trotta (Italian Medicines Agency, Rome); Antonio Addis, Neri Agabiti, Anna Maria Bargagli, Valeria Belleudi, Enrico Calandrini, Silvia Cascini, Giulia Cesaroni, Marina Davoli, Angelo Nardi (Department of Epidemiology, Lazio Regional Health Service, ASL Roma 1, Rome); Nicola Caranci, Maria Luisa Moro (Regional Health and Social Care Agency, Emilia-Romagna Region, Bologna, Italy); Roberto Gnati, Teresa Spadea (Epidemiology Unit ASL T03, Piedmont Region, Turin, Italy). We are grateful to Dr. Linda Pierattini for language editing.

The Drug Inequalities study group must be included among authors, and members should be listed as contributors in order to be indexed.

Disclaimer
The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the respective authors’ organizations.

Authors’ contributions
All the authors contributed to the study conception and design. FT supervised the project. ADF, SP and AP performed data collection and analyses. ADF, SP and FF drafted the first version of the manuscript. All authors contributed to interpretation of data. All authors read, commented, revised and approved the final version of the manuscript.

Funding
All authors declared no financial support for this work that could have influenced its outcome.

Availability of data and materials
The data that support the findings of this study are available from the Italian Medicines Agency but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request.

Declarations
Ethics approval and consent to participate
The study involving the analysis of datasets from administrative health databases established for other purposes, where data are routinely collected and kept appropriately anonymized, without the need to obtain informed consent at the time of original data collection. Moreover, in these cases, permission to use the relevant information is not required. For these reasons, Ethics approval is not required. However, all procedures performed in the study complied with relevant guidelines and regulations and the 1964 Declaration of Helsinki and its subsequent amendments or comparable ethical standards.

Consent for publication
Not applicable.

Competing interests
All authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Author details
1Italian Medicines Agency (AIFA), Via del Tritone 181, 00187 Rome, Italy.
2Regional Health and Social Care Agency, Emilia-Romagna Region, Bologna, Italy.
3Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.
4Epidemiology Unit ASL T03, Piedmont Region, Turin, Italy.

Received: 13 July 2022 Accepted: 3 October 2022
Published online: 09 November 2022
4. Art.1 LEGGE 23 dicembre 1978, n. 833, GU Serie Generale n.360 del 28–12–1978 - Suppl. Ordinario. https://www.gazzettaufficiale.it/eli/id/1978/12/28/78U0360/s/g. Accessed 15 June 2022

4. Art.1 LEGGE 23 dicembre 1978, n. 833, GU Serie Generale n.360 del 28–12–1978 - Suppl. Ordinario. https://www.gazzettaufficiale.it/eli/id/1978/12/28/78U0360/s/g. Accessed 15 June 2022

3. European Commission, Directorate-General for Health and Consumers, Meerdink, W., Meerding, W., Kunst, A., Mackenbach, J. Health inequalities: an analysis of hospitalizations with socioeconomic and sociodemographic variables at a municipality level. Epidemiol Prev. 2020;44(3):172–80. doi.org/10.1186/s12963-018-0163-7.

2. World Health Organization. A conceptual framework for action on the social determinants of health. Social Determinants of health, discussion paper 2. Geneva: World Health Organization, 2010. https://www.who.int/sdhconference/resources/ConceptualframeworkforactiononSDH_eng.pdf.

3. European Commission, Directorate-General for Health and Consumers, Meerdink, W., Meerding, W., Kunst, A., Mackenbach, J. Economic implications of socio-economic inequalities in health in the European Union, European Commission. 2010. https://oepeurope.eu/en/publication-detail-/publication/7595af76-a24c-46cc-acbe-98280eed558f. Accessed 15 June 2022

2. World Health Organization. A conceptual framework for action on the social determinants of health. Social Determinants of health, discussion paper 2. Geneva: World Health Organization, 2010. https://www.who.int/sdhconference/resources/ConceptualframeworkforactiononSDH_eng.pdf.

1. Mackenbach JP, Stirbu I, Roskam AJ, et al. European Union Working Group on Socioeconomic Inequalities in Health. Socioeconomic inequalities in health in 22 European countries. N Engl J Med. 2008;358(23):2468–81.
43. Price D, Keininger DL, Viswanad B, Gasser M, Walda S, Gutzwiller FS. Factors associated with appropriate inhaler use in patients with COPD - lessons from the REAL survey. Int J Chron Obstruct Pulmon Dis. 2018;2018(13):695–702, 2018.

44. Pasetto R, Caranci N, Pirastu R. Deprivation indices in small area studies of environment and health in Italy. Epidemiol Prev. 2011;35(5–6 Suppl 4):174–80.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.